2017 Mission Honoree

Meet our 2017 Mission Honoree:

Doug Olson, CLL Survivor

Doug Olson, was diagnosed with chronic lymphocytic leukemia (CLL) in 1996.

For six years he endured what is known as “watch and wait” meaning he was not treated, but was monitored frequently for signs that the cancer had advanced.  After six years he had to undergo chemotherapy, followed by five years of remission. But in 2009, the cancer returned and this time he did not respond to treatment.

In September 2010, Olson became one of the first patients to undergo an experimental therapy known as CART-19 cell therapy, an innovative approach supported by funding from LLS.

Doug now wants to share his story to remind everyone that while breakthrough therapies are saving lives, work still needs to be done to find cures.